ASCRS clinical advisory on intracameral moxifloxacin injection for infection prophylaxis

Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. 2 different concentrations are most commonly available in the United States for intracameral (IC) use: 0.5% (5 mg/mL) and 0.1% (1 mg/mL). The recommended volume to be injected is diffe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cataract and refractive surgery Vol. 49; no. 10; p. 1068
Main Authors: Myers, William G, Chang, David F, Shorstein, Neal H, Mah, Francis S, Mamalis, Nick, Miller, Kevin M
Format: Journal Article
Language:English
Published: United States 01.10.2023
Subjects:
Anterior Chamber
Anti-Bacterial Agents - therapeutic use
Antibiotic Prophylaxis
Cataract Extraction
Endophthalmitis - drug therapy
Eye Infections, Bacterial - drug therapy
Eye Infections, Bacterial - prevention & control
Humans
Moxifloxacin
Postoperative Complications - prevention & control
ISSN:1873-4502, 1873-4502
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Moxifloxacin solution is frequently injected at the conclusion of cataract surgery for endophthalmitis prophylaxis. 2 different concentrations are most commonly available in the United States for intracameral (IC) use: 0.5% (5 mg/mL) and 0.1% (1 mg/mL). The recommended volume to be injected is different for the 2 concentrations, and incorrect dosing can increase the risk of toxic anterior segment syndrome or endophthalmitis. In addition, the U.S. Food and Drug Administration recently published an alert regarding potential adverse events associated with intraocular compounded moxifloxacin. This clinical advisory reviews the optimal dosing of IC moxifloxacin based on current evidence.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1873-4502
1873-4502
DOI:10.1097/j.jcrs.0000000000001237